Results 21 to 30 of about 180,190 (229)

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting

BMC Ophthalmology, 2017
Background To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings over the first 2 years (24 months) of
Athanasios Vardarinos, Nitin Gupta, Raazia Janjua, Abigail Iron, Theo Empeslidis, Konstantinos T. Tsaousis   +5 more
doaj   +1 more source

Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion

Ophthalmic Surgery, Lasers and Imaging Retina, 2014
BACKGROUND AND OBJECTIVE: To determine the effectiveness and direct medical costs of treat-and-extend (TAE) intravitreal bevacizumab (IVB) for the treatment of branch retinal vein occlusion (BRVO)–associated macular edema (ME). PATIENTS AND METHODS: Retrospective chart review of 52 ...
Rush, R, Simunovic, M, Aragon, A, Ysasaga, J   +3 more
openaire   +3 more sources

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study [PDF]

British Journal of Ophthalmology, 2015
To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO).A 24-month single-masked study with patients randomised 1:1:1 to T&E+laser (n=121), T&E (n=128) or PRN (control; n=123).
Prunte C., Fajnkuchen F., Mahmood S., Ricci F., Hatz K., Studnicka J., Bezlyak V., Parikh S., Stubbings W. J., Wenzel A., Figueira J.   +10 more
openaire   +3 more sources

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

Ophthalmology and Therapy, 2020
Introduction To evaluate 1-year outcomes of intravitreal aflibercept (IVA) using a treat-and-extend (TAE) regimen for polypoidal choroidal vasculopathy (PCV) and identify the factors for patients whose treatment intervals could be extended. Methods Fifty-
Tomoko Tamachi, Takeya Kohno, Manabu Yamamoto, Kumiko Hirayama, Akika Kyo, Nobuhiko Ueda, Michiko Hirabayashi, Kunihiko Shiraki, Shigeru Honda   +8 more
doaj   +1 more source

Treat and extend regimen with aflibercept for chronic central retinal vein occlusions: 2 year results of the NEWTON study

International Journal of Retina and Vitreous, 2019
Background To determine whether aflibercept (Eylea; Regeneron Pharmaceuticals, Inc., Tarrytown, NY) could continue to extend the macular edema free interval in patients on a treat and extend (TAE) with non-ischemic central retinal vein occlusions (CRVOs)
Rahul N. Khurana, Louis K. Chang, Alok S. Bansal, James D. Palmer, Chengqing Wu, Mark R. Wieland   +5 more
doaj   +1 more source

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

Clinical Ophthalmology, 2023
Tomoko Miyakubo, Ryo Mukai, Hidetaka Matsumoto, Masahiro Morimoto, Maki Takahashi, Kazuki Nagai, Kosuke Nakamura, Junki Hoshino, Hideo Akiyama Department of Ophthalmology, Gunma University, Graduate School of Medicine, Maebashi, Gunma ...
Miyakubo T, Mukai R, Matsumoto H, Morimoto M, Takahashi M, Nagai K, Nakamura K, Hoshino J, Akiyama H   +8 more
doaj  

Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion

Ophthalmology and Therapy, 2019
Introduction To report the 52-week treatment outcomes with intravitreal injections of aflibercept using a treat-and-extend regimen for treating macular edema secondary to central retinal vein occlusion (CRVO). Methods A retrospective analysis of patients
Maria Eleftheriadou, Luke Nicholson, Giulia D’Alonzo, Peter K. F. Addison   +3 more
doaj   +1 more source

Long-term results of anti-VEGF therapy in macular edema caused by central retinal vein occlusion

Российский офтальмологический журнал, 2023
Purpose. To evaluate long-term results of anti-VEGF therapy performed in a modified “treat-and-extend” regimen in macular edema secondary to central retinal vein occlusion.Material and methods.
A. B. Galimova, V. U. Galimova
doaj   +1 more source

EXIT STRATEGY IN A TREAT-AND-EXTEND REGIMEN FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION [PDF]

Retina, 2019
Purpose: To evaluate the outcome of an exit strategy in a treat-and-extend regimen for neovascular age-related macular degeneration. Methods: Five hundred and ninety-eight eyes of 488 patients with neovascular age-related macular degeneration receiving intravitreal anti–vascular ...
Arendt, Petra, Yu, Siqing, Munk, Marion R., Ebneter, Andreas, Wolf, Sebastian, Zinkernagel, Martin S.   +5 more
openaire   +2 more sources

Faricimab Treat-and-Extend for Diabetic Macular Edema

Ophthalmology
Purpose: To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-andextend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.govidentifiers, NCT03622580 and ...
WONG, T, YOSEMITE AND RHINE INVESTIGATORS, YOSEMITE and RHINE Investigators   +2 more
openaire   +2 more sources